+1,640.0%
STX vs MRNA
+806.0%
+834.0%
-57.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | +1.3% | -0.2% | +1.0% |
| 7D | -4.4% | -13.8% | +9.5% | -3.8% |
| 30D | -22.8% | -17.7% | -5.1% | -22.2% |
| 3M | -37.3% | +14.3% | -51.6% | -37.8% |
| 6M | -28.8% | +336.0% | -364.8% | -36.4% |
| YTD | +89.9% | +575.9% | -486.0% | +62.2% |
| 1Y | +102.4% | +724.4% | -622.0% | +69.6% |
| 3Y | +629.4% | +160.8% | +468.6% | +550.5% |
| 5Y | +496.2% | -24.4% | +520.6% | +458.9% |
| All | +1,640.0% | +806.0% | +834.0% | +1,380.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling